Overview |
bs-70017r-100ul |
Aquaporin 2 (Ser261) Antibody |
WB, IP, IHC |
Specific for endogenous levels of the ~29 kDa AQP2 protein phosphorylated at Ser261. Also recognizes the glycosylated form of AQP2 at ~37 kDa. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide. |
Human, Mouse, Rat |
Dog, Bovine, Chicken, Non-Human Primate |
Specifications |
Unconjugated |
Rabbit |
Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser261 of rat aquarporin 2, conjugated to keyhole limpet hemocyanin (KLH). |
Ser261 |
Polyclonal |
IgG |
Lot Dependent |
Antigen Affinity purification from Pooled whole antiserum |
10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
Target |
25386 |
P34080 |
ADH water channel antibody, AQP 2 antibody, AQP CD antibody, AQP-2 antibody, AQP-CD antibody, AQP2 antibody, AQP2_HUMAN antibody, AQPCD antibody, Aquaporin 2 collecting duct antibody, Aquaporin CD antibody, Aquaporin-2 antibody, Aquaporin-CD antibody, Aquaporin2 antibody, Aquaporine 2 antibody, Collecting duct water channel protein antibody, MGC34501 antibody, Water channel aquaporin 2 antibody, Water channel protein for renal collecting duct antibody, WCH CD antibody, WCH-CD antibody, WCHCD antibody |
Aquaporin 2 (AQP2) is a hormonally regulated water channel located in the renal collecting duct. Mutations in the AQP2 gene cause hereditary nephrogenic diabetes insipidus in humans (Iolascon et al.,2007). A vasopressin induced cAMP increase results in the phosphorylation of AQP2 at serine-256 and its translocation from the intracellular vesicles to the apical membrane of principal cells (van Balkom et al., 2002). Recently, serine-261 has been identified as a novel phosphorylation site on AQP2 and levels of phosphorylated S261 have been shown to decrease with vasopressin treatment suggesting its involvement in vasopressin-dependent AQP2 trafficking (Hoffert et al., 2007) |
Application Dilution |
WB |
1:300-5000 |
IP |
1-2ug |
IHC |
|